Roche cancer immunotherapy fails another trial, casting doubt on emerging drug class
Dive Brief:
A drug combination including Roche’s experimental immunotherapy tiragolumab failed one of two main goals in a Phase 3 trial in a common form of lung ca...
Continue Reading →
